Operator of a real estate tech company intended to help owners and landlords in managing their properties. The company's platform provides a wide range of services such as accounting, utility bills, deposit management, incoming rent and dunning, property and tenant management, contract management, repairing and maintenance of the property, and property marketing, helping clients to save time and manage properties efficiently.
PriceHubble is a real estate analytics company that aims to enhance transparency in global real estate markets. It offers a platform powered by proprietary machine learning algorithms, which assists clients in making informed decisions by providing insights, valuation models, and forecasts related to urban developments. The company's digital solutions cater to various stakeholders in the real estate sector, including banks, asset managers, developers, property managers, and real estate agents. With a dedicated team of data scientists, engineers, and entrepreneurs, PriceHubble integrates advanced analytics into clients' daily business processes, ultimately helping them improve key performance metrics such as client conversion and rental yield. Headquartered in Zürich and with operations in Paris, Berlin, and Tokyo, the company employs over 60 professionals and has expanded its reach to five countries.
Vermietet.de is an association of Berlin entrepreneurs and investors whose vision is to make real estate ownership simple and intelligent. They know from their own experience how complex the management of a property can be - and have therefore founded rented.de.
Fincentrum is among the top three financial advisory consultant companies in the Czech Republic. It focuses on continuously delivering on excellence through its high quality advisory activities and always representing its client’s interests. With its advisors and business partners the company shares values of quality financial advisory. Advisors offer their clients a choice from the largest number of financial institutions and their products, and thus they can solve practically any possible situation of the client..
LaFinBox is a free and secure app that manages your money in all your financial institutions.
LaFinBox was created in 2015 on the initiative of Swiss Life, a leading player in the insurance and wealth management market. Founded in 1857, the group is one of Europe's leading providers of comprehensive solutions in global pensions and finance. Through a comprehensive approach, Swiss Life advisers support individuals and businesses in a variety of areas: life insurance, private banking, financial management, health, welfare, and property damage. They offer their customers a wide range of personalized solutions, adapted to the needs and evolutions of each, in the long term.
LaFinBox centralizes all financial and investment support: current accounts, bank cards, loans, passbooks, employee savings, life insurance, PEA, mortgage.
PriceHubble is a real estate analytics company that aims to enhance transparency in global real estate markets. It offers a platform powered by proprietary machine learning algorithms, which assists clients in making informed decisions by providing insights, valuation models, and forecasts related to urban developments. The company's digital solutions cater to various stakeholders in the real estate sector, including banks, asset managers, developers, property managers, and real estate agents. With a dedicated team of data scientists, engineers, and entrepreneurs, PriceHubble integrates advanced analytics into clients' daily business processes, ultimately helping them improve key performance metrics such as client conversion and rental yield. Headquartered in Zürich and with operations in Paris, Berlin, and Tokyo, the company employs over 60 professionals and has expanded its reach to five countries.
bexio AG develops and offers Web based business and accounting software. The company was formerly known as easySYS AG and changed its name to bexio AG in September, 2015. bexio AG was founded in 2013 and is based in Rapperswil, Switzerland. As of July 5, 2018, bexio AG operates as a subsidiary of Schweizerische Mobiliar Versicherungsgesellschaft AG.
Phenex Pharmaceuticals AG is a drug discovery and development company founded in 2002, based in Ludwigshafen, Germany, with additional laboratories and offices in Heidelberg. The company specializes in small-molecule drug discovery, particularly focusing on nuclear receptors, and targets various disease areas, including liver diseases, gastrointestinal disorders, and cancer. Phenex is engaged in developing innovative therapeutics, such as RORγt inverse agonists for autoimmune diseases and FXR agonists for non-alcoholic steatohepatitis. The company aims not only to create new treatments for established targets but also to explore novel molecular mechanisms, which can lead to the development of proprietary small molecules with transformative potential. Through its research, Phenex seeks to translate scientific findings into effective therapies that improve current treatment regimens for liver and cancer patients.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
iolon, Inc., is a privately held optical networking components company. The company provides high performance tunable devices for advanced fiber optic networks. iolon s initial product is a high-powered, external cavity, tunable laser source ideal for high bit rate, long haul applications. Future product lines include tunable filters, optical switches, polarization controllers, spectral monitors and universal transponders. iolon s platform technology enables advanced automation for high volume manufacturing based on patented micro-optics, MEMS and advanced servo control technologies.
Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers proteinarray services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development. In addition, it provides training services, technical and applications support, and technical service and maintenance. The company’s products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions. Zeptosens was founded in 2002 and is headquartered in Wilderswil, Switzerland.
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.